<?xml version='1.0' encoding='utf-8'?>
<document id="30336805"><sentence text="A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects ."><entity charOffset="126-142" id="DDI-PubMed.30336805.s1.e0" text="fenfluramine HCl" /><entity charOffset="175-186" id="DDI-PubMed.30336805.s1.e1" text="stiripentol" /><entity charOffset="188-196" id="DDI-PubMed.30336805.s1.e2" text="clobazam" /><entity charOffset="202-211" id="DDI-PubMed.30336805.s1.e3" text="valproate" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e0" e2="DDI-PubMed.30336805.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e0" e2="DDI-PubMed.30336805.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e0" e2="DDI-PubMed.30336805.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e0" e2="DDI-PubMed.30336805.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e1" e2="DDI-PubMed.30336805.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e1" e2="DDI-PubMed.30336805.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e1" e2="DDI-PubMed.30336805.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e2" e2="DDI-PubMed.30336805.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s1.e2" e2="DDI-PubMed.30336805.s1.e3" /></sentence><sentence text="Phase I, open-label, randomized, single-dose, 3-period crossover study assessing pharmacokinetics (PK) and safety of ZX008, a liquid oral formulation of fenfluramine (FFA) under development for adjunctive treatment of Dravet syndrome and Lennox-Gastaut syndrome, administered with and without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA), and clobazam (CLB) (STP regimen)"><entity charOffset="153-165" id="DDI-PubMed.30336805.s2.e0" text="fenfluramine" /><entity charOffset="167-170" id="DDI-PubMed.30336805.s2.e1" text="FFA" /><entity charOffset="340-351" id="DDI-PubMed.30336805.s2.e2" text="stiripentol" /><entity charOffset="353-356" id="DDI-PubMed.30336805.s2.e3" text="STP" /><entity charOffset="359-368" id="DDI-PubMed.30336805.s2.e4" text="valproate" /><entity charOffset="370-373" id="DDI-PubMed.30336805.s2.e5" text="VPA" /><entity charOffset="380-388" id="DDI-PubMed.30336805.s2.e6" text="clobazam" /><entity charOffset="390-393" id="DDI-PubMed.30336805.s2.e7" text="CLB" /><entity charOffset="396-398" id="DDI-PubMed.30336805.s2.e8" text="STP" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e5" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e0" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e5" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e1" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e5" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e2" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e3" e2="DDI-PubMed.30336805.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e3" e2="DDI-PubMed.30336805.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e3" e2="DDI-PubMed.30336805.s2.e5" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e3" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e3" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e3" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e4" e2="DDI-PubMed.30336805.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e4" e2="DDI-PubMed.30336805.s2.e5" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e4" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e4" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e4" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e5" e2="DDI-PubMed.30336805.s2.e5" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e5" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e5" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e5" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e6" e2="DDI-PubMed.30336805.s2.e6" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e6" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e6" e2="DDI-PubMed.30336805.s2.e8" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e7" e2="DDI-PubMed.30336805.s2.e7" /><pair ddi="false" e1="DDI-PubMed.30336805.s2.e7" e2="DDI-PubMed.30336805.s2.e8" /></sentence><sentence text="" /><sentence text="26 healthy adults were administered the following treatments: ZX008 0" /><sentence text="8 mg/kg; STP 3,500 mg, CLB 20 mg, VPA 25 mg/kg (max"><entity charOffset="34-37" id="DDI-PubMed.30336805.s5.e0" text="VPA" /><entity charOffset="9-11" id="DDI-PubMed.30336805.s5.e1" text="STP" /><entity charOffset="23-25" id="DDI-PubMed.30336805.s5.e2" text="CLB" /><pair ddi="false" e1="DDI-PubMed.30336805.s5.e1" e2="DDI-PubMed.30336805.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s5.e1" e2="DDI-PubMed.30336805.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s5.e1" e2="DDI-PubMed.30336805.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s5.e2" e2="DDI-PubMed.30336805.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s5.e2" e2="DDI-PubMed.30336805.s5.e0" /></sentence><sentence text=" 1,500 mg); and ZX008 0" /><sentence text="8 mg/kg + STP regimen"><entity charOffset="10-12" id="DDI-PubMed.30336805.s7.e0" text="STP" /></sentence><sentence text=" Dose periods were 17 days apart" /><sentence text=" Blood samples were obtained for 72 hours after drug administration and used to calculate non-compartmental PK parameters" /><sentence text="" /><sentence text="Statistical bioequivalence-type analysis demonstrated ZX008 had no significant impact on the PK of any drug in the STP regimen, while the STP regimen moderately affected FFA PK"><entity charOffset="170-172" id="DDI-PubMed.30336805.s11.e0" text="FFA" /><entity charOffset="115-117" id="DDI-PubMed.30336805.s11.e1" text="STP" /><entity charOffset="138-140" id="DDI-PubMed.30336805.s11.e2" text="STP" /><pair ddi="false" e1="DDI-PubMed.30336805.s11.e1" e2="DDI-PubMed.30336805.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s11.e1" e2="DDI-PubMed.30336805.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s11.e1" e2="DDI-PubMed.30336805.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s11.e2" e2="DDI-PubMed.30336805.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s11.e2" e2="DDI-PubMed.30336805.s11.e0" /></sentence><sentence text=" The 3-drug combination increased the geometric mean Cmax, AUC0-t, and AUC0-inf of FFA while reducing the Cmax and AUC0-t of its major metabolite, norfenfluramine (norFFA)"><entity charOffset="147-162" id="DDI-PubMed.30336805.s12.e0" text="norfenfluramine" /><entity charOffset="83-97" id="DDI-PubMed.30336805.s12.e1" text="FFA" /><entity charOffset="167-181" id="DDI-PubMed.30336805.s12.e2" text="FFA" /><pair ddi="false" e1="DDI-PubMed.30336805.s12.e1" e2="DDI-PubMed.30336805.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s12.e1" e2="DDI-PubMed.30336805.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s12.e1" e2="DDI-PubMed.30336805.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s12.e0" e2="DDI-PubMed.30336805.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s12.e0" e2="DDI-PubMed.30336805.s12.e2" /></sentence><sentence text=" Adverse events (AEs) were mild to moderate and resolved spontaneously" /><sentence text=" ZX008 + STP regimen co-administration to healthy adult subjects modestly impacted the number but not severity of AEs"><entity charOffset="9-11" id="DDI-PubMed.30336805.s14.e0" text="STP" /></sentence><sentence text="" /><sentence text="Results show that the STP regimen had a moderate impact on FFA and norFFA PK and ZX008 had no significant impact on the 3 STP regimen drugs"><entity charOffset="59-61" id="DDI-PubMed.30336805.s16.e0" text="FFA" /><entity charOffset="70-72" id="DDI-PubMed.30336805.s16.e1" text="FFA" /><entity charOffset="22-24" id="DDI-PubMed.30336805.s16.e2" text="STP" /><entity charOffset="122-124" id="DDI-PubMed.30336805.s16.e3" text="STP" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e2" e2="DDI-PubMed.30336805.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e2" e2="DDI-PubMed.30336805.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e2" e2="DDI-PubMed.30336805.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e2" e2="DDI-PubMed.30336805.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e0" e2="DDI-PubMed.30336805.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e0" e2="DDI-PubMed.30336805.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e0" e2="DDI-PubMed.30336805.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e1" e2="DDI-PubMed.30336805.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30336805.s16.e1" e2="DDI-PubMed.30336805.s16.e3" /></sentence><sentence text=" ZX008 would not be expected to alter the clinical response of patients to this regimen by means of an effect on PK" /><sentence text=" When administering these drugs together, a downward dose adjustment of ZX008 may be warranted" /><sentence text=" " /><sentence text="" /></document>